Overall, approximately 80% of adult grade II/III gliomas and secondary glioblastoma multiforme (GBM) harbor mutations at either Arg132 of IDH1 or Arg172 of IDH2, whereas point mutations in the TERT promoter occurred in ~75% of GBM [2–5]. Here, IDH2 is linked to central nervous system cancer.